RhumbLine Advisers
SEEL

RhumbLine Advisers’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

RhumbLine Advisers’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16
Closed -$50K – 3267
2022
Q1 		$50K Buy
16
+1
+7% +$4.3K ﹤0.01% 2974
2021
Q4 		$93K Buy
15
+1
+7% +$7.68K ﹤0.01% 2946
2021
Q3 		$134K Hold
14
– – ﹤0.01% 2964
2021
Q2 		$137K Buy
+14
New +$230K ﹤0.01% 2952

Other funds holding SEEL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's SEEL Position: Q2 2022 in Review

RhumbLine Advisers sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2022, closing a stake of 16 shares — an estimated $50K sold.

RhumbLine Advisers first reported a position in SEEL in Q2 2021 and held it in 4 quarters. The position peaked at $137K in Q2 2021. 65 funds tracked by Wall St. Rank hold SEEL as of Q2 2022.

  • RhumbLine Advisers reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • RhumbLine Advisers sold 16 Seelos Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $50K.
  • RhumbLine Advisers first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • RhumbLine Advisers's Seelos Therapeutics, Inc. Common Stock position peaked at $137K in Q2 2021.
  • 65 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.